A phase 1 study of the PI3Kδ inhibitor idelalisib in patients with relapsed/refractory mantle cell lymphoma (MCL)
2014; Elsevier BV; Volume: 123; Issue: 22 Linguagem: Inglês
10.1182/blood-2013-11-537555
ISSN1528-0020
AutoresBrad S. Kahl, Stephen E. Spurgeon, Richard R. Furman, Ian W. Flinn, Steven Coutré, Jennifer R. Brown, Don M. Benson, John C. Byrd, Sissy Peterman, Yoonjin Cho, Albert S. Yu, Wayne R. Godfrey, Nina D. Wagner‐Johnston,
Tópico(s)Cutaneous lymphoproliferative disorders research
ResumoKey Points This clinical study assessed idelalisib, a selective PI3Kδ inhibitor, in 40 patients with relapsed/refractory MCL. In a dose-escalation trial in heavily pretreated patients, an overall response rate of 40% was observed with an acceptable safety profile.
Referência(s)